Skip to main content

Advertisement

SpringerLink
Log in

FDOPA PET has clinical utility in brain tumour imaging: a proposal for a revision of the recent EANM guidelines

  • Letter to the editor
  • Published:
European Journal of Nuclear Medicine and Molecular Imaging Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Van der Borght T, Asenbaum S, Bartenstein P, Halldin C, Kapucu Ö, Van Laere K, et al. EANM procedure guidelines for brain tumour imaging using labelled amino acid analogues. Eur J Nucl Med Mol Imaging 2006;33:1374–80.

    Article  Google Scholar 

  2. Heiss WD, Wienhard K, Wagner R, Lanfermann H, Thiel A, Herholz K, et al. F-Dopa as an amino acid tracer to detect brain tumors. J Nucl Med 1996;37:1180–2.

    PubMed  CAS  Google Scholar 

  3. Becherer A, Karanikas G, Szabo M, Zettinig G, Asenbaum S, Marosi C, et al. Brain tumour imaging with PET: a comparison between [18F]fluorodopa and [11C]methionine. Eur J Nucl Med Mol Imaging 2003;30:1561–7.

    Article  PubMed  CAS  Google Scholar 

  4. Chen W, Silverman DHS, Delaloye S, Czernin J, Kamdar N, Pope W, et al. 18F-FDOPA PET imaging of brain tumors: comparison study with 18F-FDG PET and evaluation of diagnostic accuracy. J Nucl Med 2006;47:904–11.

    PubMed  CAS  Google Scholar 

  5. Chen W, Delaloye S, Cloughesy T, Mischel P, Bergsneider M, Satyamurthy N, et al. FDOPA uptake kinetics in human gliomas and the relationship to histopathologic tumor cell proliferation index Ki-67. SNM annual meeting 2006, N° 222

  6. Chen W, Delaloye S, Czernin J, Silverman DH, Pope W, Satyamurthy N, et al. Predicting response of malignant brain tumors to bevacizumab and irinotecan therapy with FLT and FDOPA PET. SNM annual meeting 2006, N° 221

Download references

Author information

Authors and Affiliations

  1. Médecine Nucléaire, Hôpital Tenon, 4 rue de Chine, 75020, Paris, France

    Jean-Noël Talbot, Khaldoun Kerrou, Françoise Montravers & Valérie Nataf

  2. Agence Française de Sécurité Sanitaire des Produits de Santé, St Denis, France

    Yanna Chevalme

Authors
  1. Jean-Noël Talbot
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Khaldoun Kerrou
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Françoise Montravers
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Valérie Nataf
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yanna Chevalme
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jean-Noël Talbot.

Additional information

The nomenclature for radiopharmaceuticals in this article follows the recommendations of the European Pharmacopoeia Commission.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Talbot, JN., Kerrou, K., Montravers, F. et al. FDOPA PET has clinical utility in brain tumour imaging: a proposal for a revision of the recent EANM guidelines. Eur J Nucl Med Mol Imaging 34, 1131–1132 (2007). https://doi.org/10.1007/s00259-007-0400-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00259-007-0400-y

Keywords

Search

Navigation